Lp(a): The Genetic Cardiovascular Risk Factor Most Physicians Never Test

What Is Lp(a)?

Lipoprotein(a) — Lp(a) — is a lipoprotein particle structurally similar to LDL but with a distinctive additional protein called apolipoprotein(a), or apo(a), covalently bound to its surface. This structural difference profoundly changes its behavior in the body. Where LDL primarily delivers cholesterol to peripheral tissues, Lp(a) has an additional thrombotic dimension: its apo(a) component shares structural homology with plasminogen, allowing Lp(a) to interfere with fibrinolysis — the body's clot-dissolving system. The result is a particle that both promotes arterial plaque formation and impairs the mechanisms that would normally dissolve arterial clots.

A Genetic Lottery

Unlike most cardiovascular risk factors, Lp(a) concentration is determined almost entirely by genetics — specifically by the LPA gene encoding the apo(a) protein. The gene exhibits extreme copy number variation, producing apo(a) isoforms of vastly different sizes and, consequently, vastly different Lp(a) concentrations. Approximately 80–90% of Lp(a) variability between individuals is explained by genetic factors, with the remainder attributable to hormonal and metabolic influences. This has a critical implication: you cannot eat, exercise, or supplement your way out of elevated Lp(a). Lifestyle optimization that dramatically reduces LDL has minimal effect on Lp(a).

How Prevalent Is Elevated Lp(a)?

Approximately 20% of the global population carries Lp(a) levels considered clinically elevated — typically defined as above 50 mg/dL or 125 nmol/L by major cardiology societies. This translates to roughly 1.4 billion people worldwide. In certain populations — particularly individuals of South Asian and Black African descent — the prevalence is substantially higher, with some studies showing rates approaching 30–35%. Despite this prevalence, Lp(a) remains absent from standard lipid panels ordered by the majority of physicians.

The Cardiovascular Risk

The evidence implicating Lp(a) in cardiovascular disease is extensive and consistent. Mendelian randomization studies — the gold standard for establishing causality from genetic epidemiology — demonstrate that elevated Lp(a) is causally associated with coronary artery disease, myocardial infarction, and stroke. The Copenhagen General Population Study, one of the largest prospective cohort studies of Lp(a), found that individuals with Lp(a) above 90 mg/dL had approximately three times the risk of myocardial infarction compared to individuals with the lowest levels.

Beyond coronary disease, elevated Lp(a) is one of the strongest known risk factors for calcific aortic valve stenosis — a condition that was previously considered a degenerative disease of aging but is now understood to have a significant genetic component mediated in part through Lp(a). The apo(a) particle appears to preferentially deposit at sites of mechanical stress in heart valves, promoting calcification over time.

Why Standard Panels Exclude It

Standard lipid panels were designed in an era when LDL-C reduction was the central therapeutic target of cardiovascular prevention. Since Lp(a) cannot be reduced by statins — and was, until recently, not amenable to pharmacological intervention — its clinical utility was considered limited in primary prevention. This reasoning is increasingly outdated. Identifying elevated Lp(a) allows for: more aggressive management of modifiable risk factors that compound with Lp(a)-driven risk; early screening of first-degree relatives who share the genetic predisposition; and access to emerging RNA-based therapies (including inclisiran and investigational anti-apo(a) small interfering RNAs) now demonstrating up to 80–90% Lp(a) reduction in clinical trials.

Who Should Be Tested

Current European Atherosclerosis Society consensus recommendations advocate for at least one lifetime Lp(a) measurement in adults. Specific populations for whom testing is particularly important include: individuals with a personal or family history of premature cardiovascular disease (defined as events before age 55 in men and 65 in women); those with apparently low traditional risk who experience cardiovascular events; individuals with familial hypercholesterolemia; and patients in whom the decision to initiate statin therapy is uncertain. Given the test's cost-effectiveness and the prevalence of undetected elevated Lp(a), a strong argument exists for universal screening at the comprehensive metabolic level.

What Elevated Lp(a) Means Clinically

An elevated result does not mean a cardiovascular event is inevitable. It means your baseline risk profile is higher than traditional testing reveals, and that risk management must be correspondingly more aggressive. Elevated Lp(a) shifts the calculus on statin initiation thresholds, aspirin use, blood pressure targets, and metabolic optimization. It argues for intensive management of every modifiable cardiovascular risk factor — because Lp(a) is the one factor that cannot itself be modified through lifestyle. At QIM Health, Lp(a) is included in our cardiovascular risk panel precisely because its absence from standard testing leaves a significant fraction of high-risk individuals unidentified until their first event.